Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Share-based Compensation: 2016-2024

Historic Share-based Compensation for Mereo BioPharma Group (MREO) over the last 9 years, with Dec 2024 value amounting to $7.4 million.

  • Mereo BioPharma Group's Share-based Compensation fell 1.38% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.6 million, marking a year-over-year increase of 13.17%. This contributed to the annual value of $7.4 million for FY2024, which is 50.08% up from last year.
  • As of FY2024, Mereo BioPharma Group's Share-based Compensation stood at $7.4 million, which was up 50.08% from $4.9 million recorded in FY2023.
  • In the past 5 years, Mereo BioPharma Group's Share-based Compensation ranged from a high of $7.4 million in FY2024 and a low of $2.0 million during FY2020.
  • Over the past 3 years, Mereo BioPharma Group's median Share-based Compensation value was $4.9 million (recorded in 2023), while the average stood at $5.7 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first fell by 4.22% in 2020, then soared by 122.48% in 2021.
  • Mereo BioPharma Group's Share-based Compensation (Yearly) stood at $2.0 million in 2020, then spiked by 122.48% to $4.5 million in 2021, then climbed by 7.12% to $4.8 million in 2022, then rose by 3.27% to $4.9 million in 2023, then skyrocketed by 50.08% to $7.4 million in 2024.